Pharmaceutical companies registered further increases in thefirst half of 2010, at paces that in some cases got as high as 40%,after they were the "winners of the crisis" last year, and theentire industry seems to be defying the current period, of strugglefor survival. The drug industry rose by 19% in the first sixmonths, according to Cegedim data quoted by pharmaceuticalcompanies' representatives. The trend, generated both by the risingdrug prices starting April 1, and by a more aggressive promotion ofexpensive products, was felt both in players' sales and profits.The "star" of this period was Zentiva, which in H1 saw its profittriple and turnover go up by 36%. In a ranking drawn up by ZF,Sanofi-Aventis came second in terms of 2009 growth. The market wasequally favourable for A&D Pharma domestic giant, which had a90% profit leap, while its sales in euros advanced by 30%. Whileduring the years prior to the crisis real estate investments werethe recipe of success, recent years have shown that pharmaceuticalcompanies were in fact a more lucrative investment.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
